Wechselwirkungen · Peyona (previously Nymusa)
Peyona 20 mg/mL solution for infusion and oral solution · Abschnitt 4.5 · PDF-Seite 5–6
HOS-121294 · Präparat HOS-095319
5 Although few data exist on interactions of caffeine with other active substances in preterm newborn infants, lower doses of caffeine citrate may be needed following co-administration of active substances which are reported to decrease caffeine elimination in adults (e.g., cimetidine and ketoconazole) and higher caffeine citrate doses may be needed following co-administration of active substances that increase caffeine elimination (e.g., phenobarbital and phenytoin). Where doubt exists about possible interactions, plasma caffeine concentrations should be measured. As bacterial overgrowth in the gut is associated with the development of necrotising enterocolitis, co- administration of caffeine citrate with medicinal products that suppress gastric acid secretion (antihistamine H2 receptor blockers or proton-pump inhibitors) may in theory increase the risk of necrotising enterocolitis (see section 4.4 and 4.8). Concurrent use of caffeine and doxapram might potentiate their stimulatory effects on the cardio- respiratory and central nervous system. If concurrent use is indicated, cardiac rhythm and blood pressure must be carefully monitored.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) cimetidine (HOS-085835) ketoconazole (HOS-084513) doxapram (HOS-121295) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-09-18T02:09:00Z · SHA-256 538bfaa1bbc4434dad321d044190ff4102a2e9d6bf1a8fbce0d4ca21d26015c6 · Passage 9a84a13742c3364eb7af1b92da653aed8a3d901e036a51feb31fc6b46834c1cd · Zeichen 550–1706 im Abschnitt